# Addex Therapeutics (ADXN) — Earnings

ADXN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/adxn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$1.44 |
| EPS estimate | $0.00 |
| EPS surprise | +0.00% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 26, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1574232/000117184326005744/f6k_082626.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a44f881f-7d62-c8fb-ffb8-3d1d4b9be016.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 26, 2026 | $0.00 | −$1.44 | 0.00% | — | — |
| Q1 2026 | Jun 25, 2026 | $0.00 | −$1.48 | 0.00% | — | $9,878.00 |
| Q3 2025 | Dec 4, 2025 | $0.00 | −$1.50 | 0.00% | $236,616.00 | $62,426.00 |
| Q2 2025 | Sep 30, 2025 | $0.00 | −$3.02 | 0.00% | $236,616.00 | $45,246.00 |
| Q3 2024 | Nov 22, 2024 | −$1.42 | −$2.69 | -89.15% | $118,308.00 | $66,014.00 |
| Q2 2024 | Sep 30, 2024 | −$1.42 | $11.38 | 899.25% | $237,318.00 | $136,329.00 |
| Q1 2024 | Jun 6, 2024 | −$0.44 | −$1.35 | -204.69% | $772,670.00 | $263,438.00 |
| Q3 2023 | Nov 29, 2023 | −$0.66 | −$4.11 | -521.24% | $662,288.00 | $376,022.00 |
| Q2 2023 | Aug 10, 2023 | −$0.83 | −$5.49 | -565.81% | $309,406.00 | $723,319.00 |
| Q1 2023 | May 11, 2023 | −$1.03 | −$5.37 | -420.36% | $309,406.00 | $561,301.00 |
| Q4 2022 | Mar 30, 2023 | −$1.03 | −$27.60 | -2575.66% | $257,838.00 | $655,971.00 |
| Q3 2022 | Nov 14, 2022 | −$1.86 | $11.42 | 715.08% | $232,054.00 | $439,816.00 |
| Q2 2022 | Aug 18, 2022 | −$2.71 | −$23.89 | -782.91% | $530,780.00 | $194,897.00 |
| Q1 2022 | May 5, 2022 | −$10.33 | −$18.27 | -76.94% | $505,567.00 | $247,678.00 |
| Q4 2021 | Mar 10, 2022 | −$12.98 | −$16.30 | -25.56% | $515,012.00 | $419,062.00 |
| Q3 2021 | Nov 4, 2021 | −$17.05 | −$14.46 | 15.21% | $414,321.00 | $830,366.00 |
| Q2 2021 | Aug 5, 2021 | −$15.75 | −$18.53 | -17.62% | $258,149.00 | $1.2M |
| Q1 2021 | May 5, 2021 | −$13.13 | −$10.51 | 19.93% | $765,864.00 | $1.0M |
| Q4 2020 | Mar 11, 2021 | $0.00 | −$10.50 | 0.00% | — | $2.1M |
| Q3 2020 | Nov 3, 2020 | $0.00 | −$15.78 | 0.00% | — | $109,607.00 |

## Frequently Asked Questions

### When did Addex Therapeutics (ADXN) last report earnings?

Addex Therapeutics last reported on Aug 26, 2026, covering fiscal Q2 2026.

### Did ADXN beat earnings estimates?

Addex Therapeutics reported EPS of −$1.44 for Q2 2026, in line with the $0.00 consensus estimate.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).